Single-use Assemblies Market - Analysis of Worldwide Industry Trends and Opportunities

According to the new market research report “Single-use Assemblies Market by Product (Bag Assembly, Filtration Assembly, Bottle Assembly, Mixing Assembly), Application (Filtration, Storage), Solution (Standard, Customized), End User (Pharmaceutical, Biopharma, CMOs, CROs) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period.

Driver: Rapid implementation and low risk of cross-contamination;

A single-use solution has numerous advantages over traditional bioprocessing technologies, due to which the adoption of single-use assemblies is growing continuously. These include the faster implementation of single-use assembly components in the bioprocess cycle and a lower risk of cross-contamination. Single-use assemblies are ergonomically designed to hold integrated single-use flow paths for faster set-up and reduced space requirements. The product design is aimed to reduce the amount of time and cost related to preparation, set-up, testing, validation, and documentation. In addition, with the elimination of the Clean-In-Place (CIP) and Sterilization-In-Place (SIP) steps, the project lead time for the implementation of single-use production plants is reduced by at least eight months as compared to stainless-steel reactors and reusable assemblies. Owing to such advantages, single-use solutions enable faster batch turnaround and product change-over.

Product cross-contamination is a major concern in the biomanufacturing industry. The potential for cross-contamination occurs when the same process equipment is used repeatedly in the process cycle. Unwanted protein contamination, for example, may reduce production yields by requiring additional purification steps, or in the worst possible case, proteins that co-purify may result in potentially fatal treatments. Since the product flow path is discarded and replaced after each batch, the risk of product cross-contamination between batches is virtually eliminated with the use of single-use assembly components. Single-use component manufacturers also typically make and assemble products in cleanrooms to ensure that their products do not introduce harmful particulates and endotoxins into a bioprocess. Such advantages are driving the adoption of single-use assemblies among end users in the biopharmaceutical pharmaceutical industries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46226549

The growth of the market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies, such as rapid implementation and the low risk of cross-contamination. The increasing biopharmaceutical RD expenditure and growing biologics market are also driving the market growth.

The biopharmaceutical pharmaceutical companies segment accounted for the largest share of the end user segment in the single-use assemblies market in 2020.

On the basis of end users, segmented into biopharmaceutical pharmaceutical companies, contract research manufacturing organizations (CROs CMOs), and academic research institutes. In 2020, the biopharmaceutical pharmaceutical companies segment accounted for the largest share of the single use assemblies market. The demand for biopharmaceuticals among the geriatric population is increasing as the elderly are more prone to diseases/disorders, which are treated using biologics. This has resulted in the increased focus of biopharmaceutical companies on developing affordable biologics at lower costs. As single-use assemblies have wide applications in each stage of the production cycle, their adoption is increasing with the growth in the production of biologics and biosimilars.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=46226549

The standard solutions segment accounted for the largest share of the solutions segment in the single-use assemblies market in 2020.

Based on solution, segmented into standard solutions and customized solutions. In 2020, the standard solutions segment accounted for the largest share of the market. The adoption of standard solutions is high in the pharmaceutical biopharmaceutical industries due to the advantages these solutions offer, such as manufacturing process efficiency with reduced capital costs, improved flexibility with the use of pre-qualified components for building assemblies, reduced implementation time, and more flexibility with production planning.

Geographically; In 2020, the Asia Pacific region accounted for the fasted growing region of the Single use Assemblies Market. This can be attributed to the growing biopharmaceutical market and biopharmaceutical manufacturing capabilities in Asian countries, rising life science research activities, increasing investments by pharmaceutical biotechnology companies, and the growth of the contract RD sector.

Prominent players operating in the single-use assemblies market are Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), Avantor, Inc. (US), and Saint-Gobain (France).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=46226549

Track and Trace Solutions Market Analysis, Segments, Key Players, Drivers, Trends and Forecast

According to the new market research report “Track and Trace Solutions Market by Product (Plant Manager, Checkweigher, Barcode Scanner, Monitoring), Technology (2D Barcode, RFID), Application (Serialization, Aggregation, Reporting), End User (Pharma, Food, Medical Devices) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 7.3 billion by 2026 from USD 4.1 billion in 2021, at a CAGR of 12.1% during the forecast period.

Opportunities: Remote authentication of products;

Traditional brand protection technologies such as anti-theft and authentication are intended to protect individual items rather than safeguard the entire supply chain. There is a high possibility of fake products being introduced at any stage in the supply chain. To combat counterfeiting and identify massive product items, a solution with automatic and non-line-of-sight capabilities is required. The demand for technologies with modular designs, which fit enterprise needs, has increased in the last few years. For instance, track and trace technologies based on RFID maintain an electronic pedigree that records the transaction information of products within the supply chain. This approach proved to be a standout for protecting the supply chain against infiltration, theft, and fraud and supporting remote authentication in the brand protection supply chain. Technologies that are scalable from a single production line to a multi-facility/multi-line infrastructure while minimizing the initial investment are projected to gain attention in the coming future.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158898570

“The Software segment accounted for the largest market share in 2020.”

Based on products, the market is segmented into software, hardware components, and standalone platforms based on product. The software segment accounted for the largest share—60.1%—of the track and trace solutions market in 2020. Market growth is largely driven by the increasing awareness about secure packaging, the rising number of counterfeit drugs and related products, and growing awareness of brand protection. In addition, regulatory compliance is further supporting the growth of this market.

The standalone platforms segment is expected to register the highest CAGR of 15.9% during the forecast period. The growth in this market is mainly attributed to the stringent government regulations for implementing serialization and UDI codes in the pharma and medical device industry, increasing pressure on pharmaceutical companies to adopt serialization, and increasing demand for standalone platforms to reduce the serialization implementation timeframe.

“The Serialization solutions segment accounted for the largest market share in 2020.”

Based on application, the track and trace solutions market is segmented into serialization solutions; aggregation solutions; and tracking, tracing, and reporting. The serialization solutions segment accounted for the largest share—62.3%—of the applications market. This segment is projected to grow at a CAGR of 12.0% during the forecast period to reach USD 2,560.9 million by 2026. Stringent regulations for the implementation of serialization solutions in packaging and supply chain applications drive this segments growth.

The tracking, tracing and reporting segment is expected to register the highest CAGR of 16.1% during the forecast period owing to the increasing number of regulations such as DSCSA, UDI, and Medical Device Reporting (MDR) for medical devices and pharmaceutical products.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=158898570

“The 2D Barcode segment accounted for the largest market share in 2020.”

Based on technology, the track and trace solutions market is segmented into linear barcodes, 2D barcodes, and radiofrequency identification (RFID). The 2D barcodes segment accounted for the largest share of 76.2% of the technology market in 2020. This segment is projected to grow at a CAGR of 12.4% to reach USD 5,641.3 million by 2026. The large share of the 2D barcodes technology segment can be attributed to the increasing use of 2D barcodes in the packaging industry. They have higher data storage capacities than linear barcodes and contain larger amounts of data with fewer variations in image size.

The RFID segment is expected to register the highest CAGR of 13.7% during the forecast period due to the growing demand for these systems in automated pharmaceutical distribution and medical devices due to low labor costs and improved visibility & planning.

“The Pharmaceutical and Biopharmaceutical Company segment accounted for the largest market share in 2020.”

Based on technology, the track and trace solutions market is segmented into linear barcodes, 2D barcodes, and radiofrequency identification (RFID). The 2D barcodes segment accounted for the largest share of 76.2% of the technology market in 2020. This segment is projected to grow at a CAGR of 12.4% to reach USD 5,641.3 million by 2026. The large share of the 2D barcodes technology segment can be attributed to the increasing use of 2D barcodes in the packaging industry. They have higher data storage capacities than linear barcodes and contain larger amounts of data with fewer variations in image size.

The RFID segment is expected to register the highest CAGR of 13.7% during the forecast period due to the growing demand for these systems in automated pharmaceutical distribution and medical devices due to low labor costs and improved visibility & planning.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=158898570

“North America was the largest regional market for track and trace solutions market in 2020”

Geographically; divided into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 42.9% of the global market, followed by Europe (33.5%). The presence of developed healthcare systems in the US & Canada; the presence of many pharmaceutical & biotechnology companies and medical device manufacturers; stringent regulations regarding serialization; and the growing medical devices market are major factors driving market growth in North America.

Asia Pacific (APAC) is the fastest-growing market and is projected to grow at the highest CAGR of 13.8% for track and trace solutions. Growing regulatory requirements in the healthcare industry to comply with manufacturing and distribution practices, the rising number of pharmaceutical and biotechnology companies, and the significant economic development in emerging Asia Pacific countries such as China and India are the major factors driving the demand for track and trace solutions in the APAC region.

Some of the prominent players in the track and trace solutions market are OPTEL GROUP (Canada), Mettler-Toledo International Inc. (US), Systech International Inc. (US), TraceLink Inc. (US), Antares Vision (Italy), SAP (US), Xyntek Inc. (US), SEA Vision Srl (Italy), Syntegon (Germany), Körber Medipak Systems AG (Switzerland), Siemens AG (Germany), Uhlmann Group (Germany), JEKSON VISION (India), Videojet Technologies, Inc. (US), Zebra Technologies Corporation (US), Axway Inc. (US), ACG Worldwide (India), Laetus GmbH (Germany), and WIPOTEC-OCS (Germany).

Medical Gas Market Growth Opportunity and Industry Forecast

According to the new market research report “Medical Gas and Equipment Market by Type (Oxygen, Nitrous Oxide, Carbon Dioxide, Gas Mixture, Vacuum System, Manifold, VIPR, Hose) Application (Respiratory, Anesthesia, Medical Imaging, Cryosurgery) End User (Hospital, Home Healthcare) – Forecast to 2023″, published by MarketsandMarkets™, the global medical gases market to grow from USD 14.83 billion in 2018 to USD 20.04 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period.

Growth Driver: Increasing prevalence of chronic diseases;

With changes in lifestyle and eating habits, the number of people suffering from obesity and related disorders across the globe has increased significantly in the last few years. The global prevalence of obesity nearly tripled between 1975 and 2016 According to the WHO, in 2016, more than 1.9 billion adults (18 years and older) were reportedly overweight, globally. Of these, over 650 million were found to be obese. Additionally, in 2016, ~340 million children and adolescents aged 5–19 were found to be overweight/obese across the globe.

Obesity is regarded as one of the major factors responsible for the increasing prevalence of chronic disorders, including heart disorders and diabetes. The WHO has stated that in the last two decades, there has been a significant increase in the prevalence of diabetes, heart diseases, and other non-communicable diseases, globally. According to the American Hospital Association, in 2015, ~149 million individuals in the US suffered from at least one chronic illness, such as hypertension, heart disease, and respiratory diseases. By 2030, this number is expected to reach 171 million. Since medical gases form a critical component of various long-term care treatments for several chronic conditions, including cardiovascular diseases, chronic respiratory diseases, and cancer, the rising prevalence of lifestyle diseases is expected to play a pivotal role in the growth of the medical gases and equipment market in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217979261

The major factors driving the growth of medical gas market include rising ageing population and sub sequent increase in chronic diseases like COPD and asthma, growing home healthcare market, and growing smoking prevalence.

The medical gases segment is expected to account for the largest share of the medical gases and equipment market

Based on product, the medical equipment market is broadly divided into medical gases and medical gas equipment. Increasing use of medical gases for the diagnosis and treatment of various respiratory diseases such as COPD, asthma, and other medical conditions such as cardiovascular and lifestyle diseases are further expected to drive the demand of medical gases during the forecast period.

Therapeutic segment will witness the highest growth in the medical equipment market.

Based on application, the medical gas market is segmented into therapeutics, diagnostics, pharmaceutical manufacturing and research, and others. The therapeutic segment is expected to account for the largest share of the global medical gases and equipment market during the forecast period of 2018 to 2023. The large share of this segment can be attributed to rising incidences of cardiovascular diseases and increasing prevalence of respiratory disorders due to lifestyle changes, rising pollution levels, and growing smoking prevalance.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=217979261

North America is expected to account for the largest share of the medical gases and equipment market in 2018, followed by Europe and the Asia Pacific. The increasing adoption of technologically advanced medical gases and equipment products, growing ageing population, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, and the presence of a large number of leading medical gases and equipment manufacturers in the region, are responsible for the large share of the North American medical gases market.

The prominent players in the medical gas and equipment market include Air Products and Chemicals, Inc. (U.S.), The Linde Group (Germany), Taiyo Nippon Sanso Corp. (Japan), SOL-SpA (Italy), Air Liquide (France), Praxair, Inc. (U.S.), Atlas Copco (Sweden), Messer Group (Germany), and GCE Holding AB (Sweden)

Global Bone Growth Stimulator Market Report Analysed by Size, Share, Growth, Industry Demand and Forecast

According to the new market research report “Bone Growth Stimulator Market by Product (Device (Implant, External), Bone Morphogenetic Protein, PRP), Application (Spinal Fusion, Delayed Union, Non-union Bone Fracture, Maxillofacial Surgery), Care Setting (Hospital, Homecare) – Global Forecasts to 2026″, published by MarketsandMarkets™, the global bone growth stimulation devices market is projected to reach USD 1.5 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.8% during the forecast period.

Growth Driver: Growing patient preference for non-invasive and minimally invasive surgical treatments

The demand for minimally invasive procedures has witnessed a significant increase owing to the advantages offered by these procedures over traditional treatment procedures. The key advantages of minimally invasive procedures include fewer operative complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infection, reduced postoperative care, and quicker recovery. Minimally invasive procedures make use of advanced technologies to diagnose and treat various diseases, including cancer. These procedures are used as an effective approach for removing cancer tumors and lymph nodes without scarring.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82341383

The Rise in the global incidence of AKI and increase in the demand for effective renal replacement therapy among ICU patients and initiatives undertaken by governments to increase the awareness about BGS therapy along with the increase in the launch of advanced BGS system area anticipated to fuel the bone growth stimulation devices market growth during the forecast period.

These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. The growing patient preference for non-invasive and minimally invasive surgical treatments, the rising prevalence of target conditions, and the growing number of sports and accident-related orthopedic injuries are the key factors driving the growth of the bone growth stimulators market. However, limited medical reimbursement for bone stimulation devices, high treatment costs associated with BMP and PRP products, and side effects associated with BMP-based orthopedic treatment are the key factors restraining the growth of bone growth stimulation devices market.

The growing demand for orthopedic injuries to support the market growth during the forecast period.

The significant rise in demand for BGS in the treatment of orthopedic patients. Moreover, the development and commercialization of BGS products also support Bone Growth Stimulator Market growth. Furthermore, many companies are expanding their BGS (PRP products) product portfolios. Similarly, the companies are also expanding their presence in the market. For instance, in 2021, Orthofix entered into an exclusive license agreement to commercialize the innovative portfolio of IGEA’s bone, cartilage, and soft tissue stimulation products in the US and Canada.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=82341383

Asia Pacific likely to emerge as the fastest-growing BGS market.

Geographically, the emerging Asian countries, such as China, India, Japan and Singapore, are offering high-growth opportunities for Bone Growth Stimulator Market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 8.7% from 2021 to 2026. Expansion of healthcare infrastructure and increase in disposable personal income, increase patient population with orthopedic disease, are factors likely to support the growth of market in the region.

The prominent players operating in the global Bone Growth Stimulator Market include Orthofix Medical, Inc. (US), DJO Finance, LLC (US), Zimmer Biomet (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US), Terumo Corporation (Japan), Ember Therapeutics, Inc. (US), Ossatec Benelux Ltd. (Netherlands), Altis Biologics (Pty) Ltd. (South Africa), Regen Lab SA (Switzerland), ITO Co., Ltd. (Japan), Elizur Corporation (US), BTT Health GmbH (Germany), Stimulate Health Inc. (Canada), VQ OrthoCare (US), Kinex Medical Company, LLC (US), Fintek Bio-Electric Inc. (Canada), Biomedical Tissue Technologies Pty Ltd. (Germany), T-Biotechnology (Turkey), DrPRP America LLC (US), Ivy Sports Medicine, LLC (US), Glofinn Oy (Finland), and REMI GROUP (India) among others.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=82341383

Digital Pathology Market - Emerging Industry Trends and Global Future Forecast

 According to the new market research report "Digital Pathology Market by Product( Artificial Intelligence, Scanner, Software, Storage), Type(Human, Veterinary), Application( Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User( Pharma, Academia, Hospitals ) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 1,371  million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period.

Browse and in-depth TOC on "Digital Pathology Market"
279 - Tables
43 - Figures
257 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844

The growth in the Digital Pathology Market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent.

The scanners segment accounted for the largest share of the Digital Pathology Market in 2020.

Based on products, the market has been segmented into scanners, software, and storage systems. The large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions.

The human pathology segment accounted for the largest share of the Digital Pathology Market in 2020.

Based on type, the global market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the market in 2020. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=844

The drug discovery, segment accounted for the largest share of the Digital Pathology Market in 2020.

Based on application, the market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the market in 2020. Growth in R&D expenditure fueled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth.

The pharmaceutical & biotechnology companies, segment accounted for the largest share of the Digital Pathology Market in 2020.

Based on end users, the global market is segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biotechnology companies segment accounted for the largest share of the Digital Pathology Market in 2020. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=844

The market in North America is projected to witness the highest growth rate during the forecast period (2021–2026).

North America accounted for the largest share of the Digital Pathology Market in 2020. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the governments in the US and Canada are major factors driving the growth of the market in North America.

The major players in the global Digital Pathology Market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Inspirata, Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), and Paige (US).

Cell Culture Market - Segmentation, Geographical Analysis & Major Key Players

According to the new market research report "Cell Culture Market by Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 41.3 billion by 2026 from USD 22.8 billion in 2021, at a CAGR of 12.6 % between 2021 and 2026.

Browse in-depth TOC on "Cell Culture Market"
690 – Tables
43 – Figures
490 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559

The growth of this market is majorly driven by the growing awareness about the benefits of cell-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growing preference for single-use technologies, the launch of advanced cell culture products, and the growing focus on personalized medicine. On the other hand, the high cost of cell biology research is restraining the growth of this market.

The consumables segment accounted for the largest share of the product segment in the cell culture market in 2020.

Based on product, the market is segmented into equipment and consumables. The cell culture equipment market is further segmented into supporting equipment, bioreactors, and storage equipment. The cell culture consumables market is segmented into sera, media & reagents, vessels, and bioreactor accessories. In 2020, the consumables segment accounted for the largest share of the market. The large share and high growth of the consumables segment can be attributed to the repeated purchase of consumables and an increase in funding for cell-based research.

The biopharmaceutical production segment accounted for the largest share of the application segment in the cell culture market in 2020. 

Based on application, the market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is further divided into monoclonal antibody production, vaccine production, and other therapeutic protein production. The tissue engineering & regenerative medicine segment is further divided into cell & gene therapy and other tissue engineering & regenerative medicine applications. The biopharmaceutical production segment is estimated to grow at the highest CAGR of 14.1% during the forecast period. The high growth of this segment is attributed to the commercial expansion of major pharmaceutical and biotechnology companies, the increasing demand for mAbs, and the growing regulatory approvals for the production of cell culture-based vaccines.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=559

The Asia Pacific region is the fastest-growing region of the cell culture market in 2020.

Based on the region, the global market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to register the highest CAGR during the forecast period. Government initiatives for research on stem cell therapy, growing geriatric population, the rising prominence of regenerative medicine research, increasing number of researchers in Japan, growth of preclinical/clinical research in China, favorable changes in foreign direct investment (FDI) regulations in the pharmaceutical industry in India, and growth of the pharmaceutical & biopharmaceutical sectors in South Korea are the major factors contributing to the growth of the market in the Asia Pacific.

Key players in the cell culture market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=559

Fractional Flow Reserve Market Professional Survey Report 2020

The report "Fractional Flow Reserve Market by Technology (Invasive Monitoring, Non-invasive Monitoring), Invasive Monitoring Product (Pressure Guidewires, FFR Measurement Systems), Application, and Region - Global Forecast to 2024", is projected to reach USD 1,081.8 million by 2024 from USD 516 million in 2019, at a CAGR of 16.0% during the forecast period.

Driver: Rising geriatric population and the subsequent growth in the prevalence of CVD;

Over the years, there has been a significant increase in the geriatric population across the globe. According to the UN World Population Ageing Report 2017, the global geriatric population (aged 60 years and above) is expected to reach 2.1 billion by 2050 from 962 million in 2017.

As this population segment is highly susceptible to CVD and other target diseases, the demand for advanced diagnostic and treatment options is expected to increase in the coming years. Changing lifestyle, smoking, hypertension, high blood cholesterol levels, physical inactivity, high BMI, and high blood sugar levels are the leading risk factors for heart disease and stroke. With the rising prevalence of CVD, the number of related diagnostic and treatment procedures is expected to increase significantly across the globe in the coming years. In this scenario, the demand for fractional flow reserve is likely to increase as it provides various benefits, such as assessing if the stenosis is required, which in turn helps in avoiding surgeries (in cases where stenosis is not needed).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=257837023

Leading Key Players and Analysis:

The key players in the fractional flow reserve market are Abbott (US), Boston Scientific (US), ACIST Medical Systems (US), Koninklijke Philips N.V. (Netherlands), Opsens, Inc. (Canada), HeartFlow, Inc. (US), Siemens Healthineers (Germany), Pie Medical Imaging (Netherlands), CathWorks (Israel), and Medis Medical Imaging Systems BV (Netherlands).

Abbott (US) held the leading position in the fractional flow reserve market. The company acquired a significant share in the FFR market through the acquisition of St. Jude Medical (US). This acquisition positioned Abbott as a major cardiology devices provider. The strategic acquisition of St. Jude Medical, a leading player in the cardiovascular and neuromodulation products market, strengthened the position of Abbott in the fractional flow reserve (FFR) market. Abbott focuses on continuous expansions to achieve optimal growth across industries and different geographic areas. It strives to maintain its position through innovation and product launches. For instance, the company invests a significant amount of its revenue in R&D activities to increase its presence in the market. It invested USD 2.30 billion, USD 2.26 billion, and USD 1.42 billion on R&D in 2018, 2017, and 2016, respectively

Geographical Analysis in Detailed?

Asia Pacific to register the highest CAGR during the forecast period

North America dominated the FFR Market in 2018. The large share of the North American fractional flow reserve market can primarily be attributed to the high healthcare spending in the region, rising prevalence of CVD and lifestyle diseases, growth in the geriatric population, large number of ongoing research activities and product launches, availability of reimbursements, and the rapid adoption of technologically advanced imaging systems.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=257837023

Industry Segmentation:

The invasive monitoring segment to account for the largest market share during the forecast period

Based on technology, the fractional flow reserve market is segmented into invasive and non-invasive monitoring. The invasive monitoring segment accounted for the largest share of the market in 2018 and will continue to do so during the forecast period. Invasive FFR monitoring is considered the gold standard for determining the hemodynamic impact of coronary lesions. This technology utilizes pressure guidewires and monitoring systems for the measurement of fractional flow reserve. The pressure guidewire measures the flow and pressure of the blood before and after the blockage to produce a ratio.

The single-vessel diseases segment will dominate the market during the forecast period.

Based on application, the FFR Market is segmented into single-vessel diseases and multi-vessel diseases. In 2018, the single-vessel disease segment accounted for the larger share of the fractional flow reserve market. The large share of this segment can be attributed to the high prevalence of single-vessel coronary artery disease.

The pressure guidewires segment is expected to grow at the highest CAGR during the forecast period

On the basis of product, the invasive monitoring market is segmented into pressure guidewires and FFR monitoring systems. The pressure guidewires segment accounted for the largest share of the market in 2018. This can be attributed to the growth in the number of PCI procedures (as a result of the rising prevalence of CVD), strong recommendation for the use of guided revascularization by measuring FFR in specific clinical scenarios, and the single-use nature of pressure guidewires, which ensures repeat purchases.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=257837023

Central Fill Pharmacy Automation Market Professional Survey Report 2021

According to the new market research report “Central Fill Pharmacy Automation Market by Product (Equipment (Medication Dispensing System, Automated Medication Compounding Systems, Workflow Management), Service (Process Optimization, Facility Design), Software), Vendor – Global Forecast to 2024″, published by MarketsandMarkets™, the Pharmacy Automation Market is projected to reach USD 656 million by 2024 from USD 381 million in 2019, at a CAGR of 11.5%.

Recent Developments;

- In 2018, TCGRx acquired Parata Systems, to expand the company’s existing growth initiatives with central fill, inventory control, and automated blister card packaging technologies.

- In 2018, ARxIUM, Inc., launched cGMP RIVA IV Compounding system for 503B facilities.

- In 2018, Swisslog Healthcare acquired Talyst Systems, LLC. With the aim of expanding Swisslog’s inpatient and outpatient pharmacy solutions along with the company’s field service network.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87188549

The increasing demand for specialty drugs being dispensed by central fill pharmacies is one of the primary drivers propelling the growth of this market. Other factors such as the need to minimize medication errors, growing patient volume (which in turn is increasing the burden on pharmacies), and the growing focus on automation to reduce labor costs are also driving market growth.

The equipment segment is expected to account for the largest share of the pharmacy automation market

The central fill pharmacy automation market, by product and service, is segmented into equipment, services, and software. The equipment segment accounted for the largest market share in 2018. A number of automated systems are used in facilities offering the advantages of freeing up manpower, allowing greater throughput, and increasing the number of processed prescriptions. These facilities form an indispensable tool for central fill pharmacies to improve the prescription assembly, verification, and delivery back to the pharmacy. This contributes to the large share of the segment.

The equipment vendors are increasing with the increasing demand for automation systems

Based on vendor, the central fill pharmacy automation market is segmented into equipment vendors and consulting vendors. The equipment vendors segment is estimated to account for the largest market share in 2018. This is mainly attributed to their broad product portfolio, vast geographic presence, strong technical expertise, and easy access to spare parts (resulting in reduced downtime).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=87188549

North America is expected to dominate the pharmacy automation market during the forecast period

In 2018, North America dominated the central fill pharmacy automation market, followed by Europe, and this trend is expected to continue during the forecast period. The rising focus on providing value-based care to patients, increase in specialty medication dispensing, growing number of medication errors, and the need for automated systems for improved compounding and dispensing are major factors that have resulted in the increased adoption of central fill pharmacy automation equipment and services in North America.

Prominent players in the central fill pharmacy automation market are ARxIUM, Inc. (US), RxSafe, LLC (US), TCGRX Pharmacy Workflow Solutions (US), McKesson Corporation (US), Omnicell, Inc. (US), ScriptPro (US), Kuka AG (Germany), Innovation (US), R/X Automation Solutions (US), Tension Packaging & Automation (US), Cornerstone Automation Systems, LLC (CASI, US), and QMSI (US)

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=87188549

Global Therapeutic Drug Monitoring Market Key Player, Trends, Analysis And Forecast

According to the new market research report “Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User – Global Forecast to 2025″, published by MarketsandMarkets™, the TDM Market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025.

Driver: Increasing preference for precision medicine;

Precision medicine is an evolving approach for disease treatment and prevention that considers individual variability in genes, environments, and lifestyles. Precision medicine involves selecting drugs wholly tailored to a patient based on disease condition and history. Although this practice is expanding into all disease areas, oncology has seen the most progress.

Currently, cancer patients are being provided treatment through combination drugs, based on studies conducted on the patient’s parameters such as systems biology, analysis of the tumor, and gene expression data in the absence and presence of pharmacological perturbation. This approach, which is currently being tested in various settings, aims to revolutionize pharmacotherapy in oncology and other disease areas. TDM can be of immense value to advance this novel way of treating patients.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443

Immunoassays is expected to hold the largest share of the TDM Market in 2020

Based on technology, segmented into immunoassays and chromatography-MS. In 2019, immunoassays segment accounted for the largest market share, due to the increasing incidence of chronic and infectious diseases and technological innovation.

Antiepileptic drugs is expected to hold the largest share of the therapeutic drug monitoring market in 2020

On the basis of class of drug, the market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs. During 2019, antiepileptic drugs held the largest share among the class of drug due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs.

Hospital laboratories segment commanded the largest share of the TDM Market in 2019

By end user, the market is segmented into hospital laboratories, commercial & private laboratories, and other end users. Hospital laboratories accounted for the largest share of the market in 2019. The large share of this segment can be attributed to factors such as the availability of advanced healthcare facilities in hospitals and the rising incidences of chronic diseases.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=155350443

North America commanded the largest share of the therapeutic drug monitoring market in 2019.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America commanded the largest share of the market. Increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region, coupled with initiatives taken by different government associations, are anticipated to boost the market growth in the region.

The major players operating in this therapeutic drug monitoring market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories (U.S.), bioMérieux (France), BÜHLMANN Laboratories (Switzerland), SEKISUI MEDICAL (Japan), Randox Laboratories (Ireland), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (United Kingdom), ARK Diagnostics, Inc. (U.S.), Chromsystems Instruments & Chemicals GmbH (Germany), Grifols (Spain)

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=155350443

Humanized Mouse and Rat Model Market Professional Survey Report 2022

The Research Report on “Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) – Global Forecast” published by MarketsandMarkets™.

The humanized mouse models market to grow from USD 73.9 million, to USD 128.9 million, at a CAGR of 9.9% during the forecast period.

The humanized rat models market is expected to reach USD 8.9 million, at a CAGR of 8.4% during the forecast period.

The Growth in Humanized Mouse and Rat Model Market can primarily be attributed to factors such as the growing demand of personalized medicine, continuous support in the form of investments and grants from the government and private sectors, increasing number of R&D activities in pharmaceutical and biotechnology companies, and the increasing number of research activities involving humanized models. Increasing production of monoclonal antibodies and rising demand for humanized rat models are expected to provide a wide range of growth opportunities for players in the market.

Opportunity: Increased production of monoclonal antibodies;

With personalized medicine gaining in importance, monoclonal antibodies (mAbs) showcase an enormous potential to treat a wide range of diseases. This is a positive indicator for market growth as mouse models are extensively used in the production of mAbs. Researchers have replaced few parts of mouse antibodies with human components; the final antibodies with a mixture of human and mouse components are known as chimeric antibodies. Some monoclonal antibodies are now entirely human as a larger portion of the human component is engrafted in the mouse antibody.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

The oncology segment commanded the largest share of the humanized rat models market

By application, Categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the humanized mouse models market in 2017. The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.

Cell-based humanized mouse models to grow at the highest CAGR during the forecast period

By type, Categorized into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017–2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.

The cell-based humanized mouse models segment is further categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment commanded the largest share of the cell-based humanized mouse models market and is expected to grow at the highest CAGR during the forecast period. CD34 mouse models are used as in vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. They are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Geographically; North America dominated the global humanized mouse models market. Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

Taconic is the second most leading players in the global humanized mouse and rat model market. The company is a provider of cell based and genetically modified mice models and supporting services such as custom model generation, imaging studies, and surgical services. The firm also has other distribution networks in India, Japan, and Singapore. A broad distribution network and a wide range of humanized mouse strains position the firm as one of the major players in the global cell based and genetic humanized mouse model market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=131763955